New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday 20 November 2026
Export PCSA’s income statement to Excel — free account
Heatwurx Inc.
PCSA- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
1.67
0.03
−1.76%
Follow PCSA
Alert me
Analysts’ price targets Wall Street, collected weekly
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | 0 | — | 40 | — | — | — | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (2) | (2) | (5) | (4) | (15) | (12) | (27) | (11) | (12) | (14) | (193) | +24.3% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (2) | (2) | (4) | (3) | (14) | (11) | (27) | (11) | (12) | (14) | (193) | +24.3% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (228.93) | (210.08) | (350.14) | (350.00) | (960.92) | (375.00) | (850.00) | (212.00) | (96.75) | (10.36) | (58.78) | (29.1%) | ||||||
| Cash flow | (256.55) | (177.91) | (346.53) | (247.76) | (209.55) | (284.88) | (298.29) | (153.59) | (91.87) | (8.70) | (4.59) | (31.3%) | ||||||
| Capex | (2.83) | (2.22) | (2.08) | 0.00 | 0.00 | 0.00 | 0.00 | (0.05) | (0.03) | (0.65) | (0.39) | (15.1%) | ||||||
| Free cash flow | (259.38) | (180.13) | (348.62) | (247.76) | (209.55) | (284.88) | (298.29) | (153.64) | (91.90) | (9.35) | (4.99) | (30.9%) | ||||||
| Book value | 269.90 | 40.13 | 906.64 | 721.86 | 1,529.30 | 832.85 | 232.01 | 95.03 | 13.86 | 4.26 | (60.99) | (36.9%) | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | +75.2% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (2) | (2) | (4) | (3) | (3) | (9) | (10) | (8) | (11) | (11) | (14) | +20.3% | |||||
| Capex | 0 | 0 | 0 | — | — | — | — | 0 | 0 | (1) | (1) | +48.8% | ||||||
| Free cash flow | (2) | (2) | (4) | (3) | (3) | (9) | (10) | (8) | (11) | (12) | (15) | +21.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 2 | 0 | 1 | 0 | 15 | 17 | 7 | 5 | 0 | 3 | 180 | +4.9% | |||||
| Net debt | (2) | 0 | (2) | 0 | (15) | (16) | (7) | (5) | (1) | (6) | (180) | +11.4% | ||||||
| Shareholders’ equity | 2 | 0 | 10 | 8 | 23 | 25 | 7 | 5 | 2 | 6 | (181) | +10.5% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (155.28) | (69.42) | (48.69) | (33.08) | (79.86) | (44.23) | (156.34) | (154.40) | (262.87) | (245.66) | (203.76) | (90.4) pt | |||||
| ROIC | (682.35) | 0.00 | (34.53) | (29.74) | (125.00) | (84.38) | (1,309.15) | (2,530.28) | (1,491.78) | (21,694.32) | 0.00 | (21,012.0) pt | ||||||
| ROE | (1,329.47) | (140.61) | (74.75) | (43.64) | (93.14) | (47.20) | (166.43) | (178.52) | (354.51) | (372.96) | 220.06 | +956.5 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 1 | 13 | 15 | 13 | 14 | 15 | 15 | 13 | 10 | 12 | — | +31.8% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2015 · latest quarter Mar 2016 · fundamentals updated 18 Nov 2026
Heatwurx Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| RVPH Reviva Pharmaceuticals Holdings, Inc. | $5.0M | — (loss-making) | — | — | n/m | +60.92% (above 0%: growing) | — | 0.00% | Compare |
| NIKI Niki BioSolutions, Inc. | $5.0M | — (loss-making) | 31.9× FY24e | −32.36% (below 0%: shrinking) | — | +58.14% (above 0%: growing) | (154.22%) | 0.00% | Compare |
| LTRN Lantern Pharma Inc. | $4.9M | — (loss-making) | — | — | n/m | +25.31% (above 0%: growing) | 0.00% | 0.00% | Compare |
| PULM Pulmatrix, Inc. | $4.9M | — (loss-making) | — (loss-making) | −99.86% (below 0%: shrinking) | n/m | +25.32% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CDIO Cardio Diagnostics Holdings, Inc. | $4.9M | — (loss-making) | — (loss-making) | +24.14% (above 0%: growing) | n/m | +2.59% (above 0%: growing) | 100.00% | (48,061.11%) | Compare |
| PCSA Heatwurx Inc. | $4.8M | — (loss-making) | — | −64.29% (below 0%: shrinking) | n/m | −48.55% (below 0%: shrinking) | 0.00% | 0.00% | |
| JAGX Jaguar Animal Health, Inc. | $4.7M | 0.0× | — (loss-making) | −24.00% (below 0%: shrinking) | n/m | −3.92% (below 0%: shrinking) | 73.24% | (257.06%) | Compare |
| CANF Can-Fite Biopharma Ltd | $4.6M | — (loss-making) | — (loss-making) | −1.18% (below 0%: shrinking) | n/m | +12.63% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SKYE Skye Bioscience, Inc. | $4.6M | — (loss-making) | — | −34.71% (below 0%: shrinking) | n/m | +61.34% (above 0%: growing) | 72.71% | 0.00% | Compare |
| Median of peers | $4.9M | — | — | −28.18% | — | +25.32% | 72.71% | 0.00% |
Pay and ownership Proxy statement filed 22 October 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 673.30k | 565.07k | 2.00 |
| 2024 | 521.03k | 288.39k | 13.00 |
| 2023 | 472.85k | 428.85k | 100.00 |
Ownership
Directors and executive officers, together
12.30%
The Chiliz Group
10.90%
Entities affiliated with CVI Investments, Inc.
6.70%
Entities affiliated with Soleus Capital
5.80%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement
Heatwurx Inc. (PCSA) Latest News
- Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Financing to Advance BTK Inhibitor Pipeline InvestorsHub
- PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS
- Processa Pharmaceuticals and BullFrog AI Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV ACCESS Newswire
- Processa Pharmaceuticals Provides Portfolio and Business Update GlobeNewswire
- Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate GlobeNewswire
- Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results GlobeNewswire
- Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer GlobeNewswire
- Processa Pharmaceuticals Provides Product Pipeline and Financial Update GlobeNewswire
- Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri GlobeNewswire
- Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer GlobeNewswire
20 more headlines
- Top Midday Gainers MT Newswires
- Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
- Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely? Simply Wall St.
- Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025 GlobeNewswire
- BC-Most Active Stocks Associated Press Finance
- Processa Pharmaceuticals, Inc. (PCSA) Secures Buy Rating on Portfolio Progress
- Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering GlobeNewswire
- Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting
- Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025 GlobeNewswire
- Processa Pharmaceuticals, Inc. (PCSA): Among the Cheapest Stocks Insiders Are Buying Recently Insider Monkey
- Favourable Signals For Processa Pharmaceuticals: Numerous Insiders Acquired Stock Simply Wall St.
- Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules GlobeNewswire
- Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September GlobeNewswire
- Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer GlobeNewswire
- Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer GlobeNewswire
- Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference GlobeNewswire
- Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research GlobeNewswire
- Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial GlobeNewswire
- Insider Buyers At Processa Pharmaceuticals Recover Some Losses, But Still Down US$40k Simply Wall St.
- Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference GlobeNewswire